PulseMedica is pioneering a groundbreaking platform aimed at revolutionizing the diagnosis and treatment of vitreoretinal diseases, particularly focusing on symptomatic vitreous opacities, commonly known as eye floaters. The company is developing a non-invasive system that utilizes advanced imaging technology to screen and treat these conditions effectively. Their platform incorporates high-resolution real-time imaging, enhanced laser accuracy, and automated treatment planning, which collectively aim to provide a safe and efficient solution for millions suffering from vision impairments related to eye floaters and other retinal diseases.

The technology being developed by PulseMedica is characterized by its image-guided laser treatment capabilities, which leverage 3D computer vision and real-time tracking to ensure precision and safety during procedures. This innovative approach not only addresses the significant unmet need for effective treatment options but also positions PulseMedica as a potential leader in the ophthalmic medical device sector. With ongoing clinical validation and a commitment to enhancing the quality of life for individuals affected by eye diseases, PulseMedica is poised to make a substantial impact in the field of ophthalmology.

Canada

PulseMedica has developed a proprietary real-time 3D imaging and laser targeting system for precise retinal surgery. Our patented next generation ultrafast femtosecond laser ophthalmic treatment will enable treatment for retinal diseases such as age-related macular degeneration (AMD) and glaucoma, for which there is currently no cure.
PulseMedica is a company based out of Edmonton, AB, Canada.

Eye Diseases

10235 101st NW, Edmonton, Alberta, CA, T5J 3E8

PulseMedica

Company Details